276 related articles for article (PubMed ID: 34858000)
1. The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome.
Liu Z; Wu X; Hwang ST; Liu J
Ann Dermatol; 2021 Dec; 33(6):487-496. PubMed ID: 34858000
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
4. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
6. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
7. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
Liu KL; Tsai WC; Lee CH
PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
[TBL] [Abstract][Full Text] [Related]
8. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
9. Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.
Belfrage E; Ek S; Johansson Å; Brauner H; Sonesson A; Drott K
JMIR Res Protoc; 2024 Apr; 13():e55723. PubMed ID: 38436589
[TBL] [Abstract][Full Text] [Related]
10. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
11. Immunological milieu in mycosis fungoides and Sézary syndrome.
Miyagaki T; Sugaya M
J Dermatol; 2014 Jan; 41(1):11-8. PubMed ID: 24438139
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides and Sézary syndrome.
Lee H
Blood Res; 2023 Apr; 58(S1):66-82. PubMed ID: 37105561
[TBL] [Abstract][Full Text] [Related]
13. The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome.
Błażewicz I; Olszewska B; Stawczyk-Macieja M; Jaśkiewicz M; Nowicki RJ; Sokołowska-Wojdyło M
Postepy Dermatol Alergol; 2021 Apr; 38(2):289-294. PubMed ID: 34408597
[TBL] [Abstract][Full Text] [Related]
14. A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.
Vonderheid EC; Kantor GR; Telang GH; Bujanouskas P; Kadin ME
J Cutan Pathol; 2019 Dec; 46(12):913-924. PubMed ID: 31403211
[TBL] [Abstract][Full Text] [Related]
15. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
16. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses.
Gettler SL; Fung MA
Dermatol Online J; 2005 Dec; 11(3):6. PubMed ID: 16409902
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
19. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
20. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Fujii K
Front Oncol; 2018; 8():198. PubMed ID: 29915722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]